Last reviewed · How we verify
Alnovin (FENDOSAL)
Alnovin (generic name: FENDOSAL) is a fendosal drug. It is currently in Phase 2 development.
Alnovin works by inhibiting the activity of Plasminogen activator inhibitor 1 (PAI-1), a protein that helps regulate blood clot formation.
Alnovin (FENDOSAL) is a small molecule drug developed to target Plasminogen activator inhibitor 1 (PAI-1), a protein involved in blood clot formation. Its exact commercial status and approved indications are unknown. As a fendosal, it is designed to modulate PAI-1 activity, potentially treating conditions related to excessive blood clotting. However, its development and approval status are unclear. Further research is needed to determine its efficacy and safety profile.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | FENDOSAL |
|---|---|
| Drug class | fendosal |
| Target | Plasminogen activator inhibitor 1 |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 2 |
Mechanism of action
Think of blood clots like a traffic jam in your blood vessels. PAI-1 is like a traffic cop that helps keep the clots from forming. Alnovin is like a special signal that tells the traffic cop to let the blood flow freely, reducing the risk of clots.
Approved indications
Common side effects
Key clinical trials
- Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults (PHASE1,PHASE2)
- Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alnovin CI brief — competitive landscape report
- Alnovin updates RSS · CI watch RSS
Frequently asked questions about Alnovin
What is Alnovin?
How does Alnovin work?
What is the generic name of Alnovin?
What drug class is Alnovin in?
What development phase is Alnovin in?
What does Alnovin target?
Related
- Drug class: All fendosal drugs
- Target: All drugs targeting Plasminogen activator inhibitor 1
- Therapeutic area: All drugs in Hematology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing